Ran Reshef

机构：Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University · ORCID：0000-0003-2185-9546

发表论文 461 篇 · 总被引 9208 次 · h-index 44

代表论文

• Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL (2026 · Blood · 被引 3)
• Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies (2026 · Transplantation and Cellular Therapy · 被引 2)
• Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma. (2026 · Journal of Clinical Oncology · 被引 1)
• Hematopoietic Cell Transplant Access and Patient Diversity (2026 · JAMA Network Open · 被引 1)
• CAR T-cells in multiple myeloma: the race to the start line (2025 · Bone Marrow Transplantation · 被引 1)
• Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025 · Blood Immunology & Cellular Therapy · 被引 1)